Purple Biotech Ltd SEC Filings

Purple Biotech Ltd. (PPBT) announced an Extraordinary General Meeting of Shareholders to be held on December 15, 2025 at 4:30 p.m. Israel time at its executive offices, 4 Oppenheimer Street, Science Park, Rehovot, Israel.

The company furnished a Notice and Proxy Statement (with a Voting Slip for ordinary shareholders) as Exhibit 99.1. BNY Mellon, the ADS depositary, will distribute a Voting Instruction Form to ADS holders (attached as Exhibit 99.2). The materials are incorporated by reference into existing Form S-8 and Form F-3 registration statements.

Purple Biotech Ltd. (PPBT) furnished a Form 6-K reporting that on October 20, 2025 it issued a press release titled “Purple Biotech Announces Receipt of Nasdaq Regarding Minimum Bid Price Notification.”

The press release is included as Exhibit 99.1. This filing serves as a notice to investors about the company’s receipt of a Nasdaq minimum bid price notification and provides the related disclosure via the attached exhibit.

Purple Biotech Ltd. (PPBT) is a clinical-stage pharmaceutical company focused on oncology candidates including NT219, CM24 and IM1240. The prospectus supplement outlines ongoing and planned clinical programs, collaborations, capitalization items and offering mechanics. NT219 completed a Phase 1 dose-escalation study showing anti-tumor activity in recurrent/metastatic head and neck cancer and an investigator-initiated Phase 2 study with University of Colorado was initiated in June 2025. CM24 is in a randomized open-label Phase 2 study in pancreatic ductal adenocarcinoma in collaboration with Bristol Myers Squibb, with interim data expected in the second half of 2023 and topline by end of 2024. The company completed corporate actions changing ADS ratios and a 1:20 share consolidation in 2019. Financing programs include a Sales Agreement with Jefferies for up to USD 50,000,000 and various warrants and ADS offerings. The filing emphasizes significant risks: operating losses, need for additional capital, reliance on third parties for manufacturing and trials, regulatory uncertainty and IP and geopolitical risks.

Purple Biotech Ltd. received a joint Schedule 13G from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting shared beneficial ownership of 139,632,475 ordinary shares, representing 9.99% of the class as of September 10, 2025. The filing explains those shares include issued shares and shares issuable on exercise of two warrants, but each warrant contains a blocker provision preventing exercise that would increase beneficial ownership above 9.99%. The reporting persons state the holdings were not acquired to change or influence issuer control and filed a joint filing agreement.

Purple Biotech Ltd. received a Schedule 13G from Lincoln Alternative Strategies LLC reporting beneficial ownership of 605,000 American Depositary Shares, equal to 9.94% of the class. Each ADS represents 200 ordinary shares, and the filing bases the percentage on 6,085,450 common shares outstanding as of Sept 4, 2025. Lincoln reports sole voting and dispositive power over all 605,000 ADS and certifies the position was not acquired to change or influence control. The filing is signed by Stephen Temes as Managing Member on Sept 9, 2025. The issuer's principal office is listed in Rehovot, Israel.

Purple Biotech Ltd.'s Schedule 13G/A filed by Orca Capital AG reports beneficial ownership of 306,394 American Depositary Shares (ADSs), representing 4.9% of the class on a post-offering basis. Each ADS represents 200 ordinary shares, and the ownership percentage is calculated using 6,085,450 ADSs outstanding after the issuer's registered offering.

The filing discloses that Orca has sole voting and dispositive power over all 306,394 ADSs and excludes 1,832,495 ADSs issuable upon exercise of Series B warrants held by Orca, which are subject to a 4.99% exercise blocker that prevents Orca from exercising warrants to exceed 4.99% ownership.